Segment Information (Schedule of Total Revenues of Top Selling Products) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended				6 Months Ended
	Jun. 30, 2014		Jun. 30, 2013		Jun. 30, 2014 drug		Jun. 30, 2013
Revenue, Major Customer [Line Items]
Revenues	$ 295,405		$ 233,669		$ 584,489		$ 523,865
Number of other insignificant generic drugs					80
Par Pharmaceutical [Member]
Revenue, Major Customer [Line Items]
Revenues	278,834		215,115		552,640		487,917
Par Pharmaceutical [Member] | Budesonide (Entocort EC) [Member]
Revenue, Major Customer [Line Items]
Revenues	38,266		45,027		75,615		95,430
Par Pharmaceutical [Member] | Bupropion Er Wellbutrin [Member]
Revenue, Major Customer [Line Items]
Revenues	18,423		11,565		34,765		19,817
Par Pharmaceutical [Member] | Divalproex (Depakote) [Member]
Revenue, Major Customer [Line Items]
Revenues	15,511		(7,653)		35,917		(6,227)
Par Pharmaceutical [Member] | Propafenone Rythmol Sr [Member]
Revenue, Major Customer [Line Items]
Revenues	15,266		17,337		36,377		34,496
Par Pharmaceutical [Member] | Metoprolol Succinate ER (Toprol-XL) [Member]
Revenue, Major Customer [Line Items]
Revenues	12,096		13,527		26,213		32,929
Par Pharmaceutical [Member] | Lamotrigine (Lamictal XR) [Member]
Revenue, Major Customer [Line Items]
Revenues	10,262		10,535		20,396		30,646
Par Pharmaceutical [Member] | Rizatriptan (Maxalt) [Member]
Revenue, Major Customer [Line Items]
Revenues	1,597		3,466		3,795		37,014
Par Pharmaceutical [Member] | Other [Member]
Revenue, Major Customer [Line Items]
Revenues	162,427	[1]	113,115	[1]	309,137	[1]	228,838	[1]
Par Pharmaceutical [Member] | Other product related royalty streams [Member]
Revenue, Major Customer [Line Items]
Revenues	4,986	[2]	8,196	[2]	10,425	[2]	14,974	[2]
Strativa [Member]
Revenue, Major Customer [Line Items]
Revenues	16,571		18,554		31,849		35,948
Strativa [Member] | Other [Member]
Revenue, Major Customer [Line Items]
Revenues	(35)		(236)		(46)		(479)
Strativa [Member] | Other product related royalty streams [Member]
Revenue, Major Customer [Line Items]
Revenues	655	[2]	971	[2]	1,467	[2]	1,871	[2]
Strativa [Member] | Megace ES [Member]
Revenue, Major Customer [Line Items]
Revenues	7,779		11,018		15,932		21,553
Strativa [Member] | Nascobal Nasal Spray [Member]
Revenue, Major Customer [Line Items]
Revenues	$ 8,172		$ 6,801		$ 14,496		$ 13,003

[1] The further detailing of revenues of the other approximately 80 generic drugs was not considered significant to the overall disclosure due to the lower volume of revenues associated with each of these generic products. No single product in the other category was significant to total generic revenues for the six-month periods ended June 30, 2014 and 2013.

[2] Other product related revenues represents licensing and royalty related revenues from profit sharing agreements.